相关实验视频

Updated: Mar 17, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

ангиотензин 1-7 调节原瘤基因Mas受体的动力学和激活

Ekrem Yasar¹, Segun Dogru², Erol Eroglu³

¹Department of Biophysics, Erzincan Binali Yildirim University, Erzincan, Turkey.

Journal of molecular recognition : JMR

|March 15, 2026

概括

马斯受体 (MasR) 使用一种新型的活性 anchor 机制,而不是紧固件模型,来调节心脏保护作用. 这一发现为针对ACE2 / 血管新生素1-7/MasR轴的治疗益处提供了新的策略.

科学领域:

生物化学生物化学
结构生物学结构生物学
药理学药理学是指药理学的学科.

背景情况:

马斯受体 (MasR) 是一种G蛋白结合受体 (GPCR),在氨酸-氨酸系统 (RAS) 中对 ангиотензин 1-7 (Ang1-7) 的心脏保护作用至关重要.
了解MasR激活机制对于治疗开发至关重要,但实验结构数据一直缺乏.

研究的目的:

阐明Mas受体的联结体诱导激活动态的分子机制.
为了研究 ангиотензин 1-7. 的部分激素特征的结构基础.

主要方法:

利用1微秒的全原子分子动力学 (MD) 模拟对一个AlphaFold模拟的MasR.
采用能量网络分析来研究连接体诱导的激活动态.
计算结合能量和形状可塑性.

主要成果:

发现了一种新的"主动"机制,挑战了传统的静电模型.
已证明, ангиотензин 1-7 激活特定的集群 (SER109/PHE112) 来稳定独特的脱活性状态.
观察到NPxxY动机和细胞内前庭扩张的完全激活,而TM6仍然处于紧的构造.

结论:

提供了对Angiotensin 1-7在MasR中的部分激素活性的结构性理由.
提出了一个新的机制框架,以准ACE2 / 血管新生素1-7/MasR轴.
建议药物设计应侧重于稳定这种紧的活性状态,而不是最大的受体开放.

关键词:

ангиотензин 177 的使用情况.在GPCR中,GPCR是指GPCR.更多关于 MasRR 的文章分子建模分子建模受体激活受体的激活方式

更多相关视频

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Published on: March 27, 2017

相关概念视频

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...